The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Opdivo-Yervoy Combo Expands Label for Colorectal Cancer in Taiwan: Ono
Ono Pharmaceutical said on January 14 that its PD-1 inhibitor Opdivo (nivolumab) has received an additional indication for certain colorectal cancers in Taiwan as a combination therapy with the CTLA-4 inhibitor Yervoy (ipilimumab).The label expansion, granted to Ono’s Taiwan subsidiary,…
To read the full story
Related Article
- Opdivo-Yervoy Combo Approved for 1st Line HCC in Taiwan
July 29, 2025
- Opdivo Approved for 1st Line Bladder Cancer Use in Taiwan: Ono
October 11, 2024
BUSINESS
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
- Rakuten Joins Hands with LOTTE Biologics to Boost Production for Photoimmunotherapy
January 15, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…